<DOC>
	<DOCNO>NCT00700427</DOCNO>
	<brief_summary>LYDO multi-center study enroll approximately 1925 adult outpatient Attention Deficit/Hyperactivity Disorder ( ADHD ) . Patients receive , open label condition , atomoxetine 100 mg/day acute , open-label part study . Those patient meet response criterion continue blind phase study year . During period , patient respond atomoxetine randomize continue treatment atomoxetine placebo ( neither patient investigator know patient receive atomoxetine placebo ) .</brief_summary>
	<brief_title>A Long Term Study Medication Adults With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Adults Male female Must meet AttentionDeficit/Hyperactivity Disorder ( ADHD ) accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision™ ( DSMIVTR™ ) criteria Comorbidity major psychiatric disorder Clinically significant depression anxiety Patients significant medical condition Current alcohol/drugs abuse/dependence Concomitant exclude medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Adult</keyword>
	<keyword>long term</keyword>
	<keyword>maintenance response</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
</DOC>